Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals's GHG Emissions Data Preview
In 2024, Glenmark Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Glenmark Pharmaceuticals has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Glenmark Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Glenmark Pharmaceuticals amounted to 85,087 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Glenmark Pharmaceuticals increased by 8.87%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Glenmark Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Glenmark Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Glenmark Pharmaceuticals were 15,455 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Glenmark Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2021, Glenmark Pharmaceuticals's Scope 1 emissions have increased by 31.95%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2023), Glenmark Pharmaceuticals's Scope 1 emissions increased by 15.83%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Glenmark Pharmaceuticals's Scope 2 emissions?
In 2024, Glenmark Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 69,632 tCOâ‚‚e without specifying the calculation method.
Has Glenmark Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2021, Glenmark Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Glenmark Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint.
Compared to the previous year (2023), Glenmark Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Glenmark Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Glenmark Pharmaceuticals use for Scope 2 reporting?
In 2024, Glenmark Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.
Glenmark Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Glenmark Pharmaceuticals's Value Chain Emissions
In 2024, Glenmark Pharmaceuticals reported 171,146 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2024 disclosure of Glenmark Pharmaceuticals includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Glenmark Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Glenmark Pharmaceuticals's Scope 3 emissions?
In 2024, Glenmark Pharmaceuticals reported total Scope 3 emissions of 171,146 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.
Has Glenmark Pharmaceuticals reduced its Scope 3 emissions over time?
Since 2021, Glenmark Pharmaceuticals's Scope 3 emissions have remained relatively stable, indicating that Glenmark Pharmaceuticals 's emissions have plateaued with no significant change in its value chain footprint.
Compared to the previous year (2023), Glenmark Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that Glenmark Pharmaceuticals 's emissions have plateaued with no significant change in its value chain footprint.
What categories of Scope 3 emissions does Glenmark Pharmaceuticals disclose?
In 2024, Glenmark Pharmaceuticals reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol.
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Glenmark Pharmaceuticals's Scope 3 emissions?
In 2024, the largest contributors to Glenmark Pharmaceuticals's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 48,402 tCOâ‚‚e (28.28%)
- Employee Commuting (Cat. 7): 46,333 tCOâ‚‚e (27.07%)
- Capital Goods (Cat. 2): 24,788 tCOâ‚‚e (14.48%)
Glenmark Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Glenmark Pharmaceuticals's Total Carbon Footprint
In 2024, Glenmark Pharmaceuticals reported a total carbon footprint of 256,233 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 1.19% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Glenmark Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 66.79% of the company's total carbon footprint, followed by Scope 2 emissions at 27.18%.